Aayush Wellness reports 10.6% rise in first-half income

Aayush Wellness experienced an increase in consolidated income and profit for the first half of fiscal 2027. The company reported an impressive rise in both consolidated income and profit after tax. Standalone income also showed significant growth compared to the preceding quarter. Aayush Wellness is launching new products to expand its presence in preventive healthcare and nutraceutical markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pvcVQ2H
via IFTTT

Read More

Govt plans instant ban on manufacturing of drugs failing key quality tests

Pharma companies could have their drug licenses suspended immediately if quality tests indicate failure. The health ministry's proposed changes aim to protect public health by enforcing swift action on substandard medications. Regulators would take action upon receiving a government analyst's report declaring a drug not of standard quality. Manufacturers would need to perform a root cause analysis and implement corrective actions to lift the suspension.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JWATw2S
via IFTTT

Read More

Inside Park Hospitals' regional playbook: Why North India depth matters more than national reach

Park Hospitals is on an ambitious expansion journey, targeting around 6,600 beds by December 2028 across North India. Their strategy focuses on building hospitals in close proximity for better operational efficiency. The new Prayagraj initiative underscores a successful public-private partnership and illustrates their commitment to enhance healthcare capacity, ultimately improving patient care and resource management in the region.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XBV846w
via IFTTT

Read More

HRV Pharma buys Germany's Phatebo

The acquisition marks virtual pharmaceutical company HRV's entry beyond active pharmaceutical ingredients (APIs) into finished formulations, giving it its first finished formulations business alongside a licenced operating entity in Germany.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QKt3eqY
via IFTTT

Read More

NPPA updates list of reduced MRP of 1,085 anti-cancer drugs

The National Pharmaceutical Pricing Authority updated the maximum retail price for 1,085 anti-cancer medicines. This revision follows a previous decrease of prices for 543 anti-cancer drugs announced on October 28. The updated list contains prices based on information submitted by pharmaceutical companies up to November 3. The NPPA will continuously update this list as more manufacturers submit revised prices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Nwgr3iq
via IFTTT

Read More

Alkem Laboratories appoints Amrut Naik as CEO

Alkem Laboratories announced the appointment of Amrut Naik as its new Chief Executive Officer. His appointment is effective from November 11, following board approval and nomination committee recommendations. Naik has more than 26 years of experience in various areas, including pharmaceuticals and biologics. He holds both a bachelor's and master's degree in pharmaceutical science alongside a PhD in pharmacology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qhj5Lzp
via IFTTT

Read More

High Court restrains NPPA from action against AstraZeneca

The Delhi High Court has issued a temporary restraining order against the NPPA's actions toward AstraZeneca Pharma. This order remains in effect until the next hearing date, January 11. AstraZeneca has argued that its product may not fall under controlled drug prices. The NPPA has accused AstraZeneca of overcharging for the inhaler from May 2016 to November 2025. AstraZeneca denies these allegations and claims compliance with the price regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/91SKhc4
via IFTTT

Read More